A clinical study testing revumenib, a novel targeted treatment, found 40% of patients with acute leukemia had complete response and showed how the cancer cells resist the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Researchers at UT Southwestern Medical Center have discovered how healthy bacteria can escape the intestine, travel to lymph nodes and cancerous tumors elsewhere in the body, and boost the effectiveness of certain immunotherapy drugs.
Data from the phase III DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, were published in The New England Journal of Medicine. Results from this study were previously presented at the European Society for Medical Oncology Congress in September 2022.
Patients with high-risk melanoma who received the immunotherapy drug Keytruda (pembrolizumab) both before and after surgery to remove cancerous tissue had a significantly lower risk of their cancer recurring than similar patients who received the drug only after surgery.
Positive high-level results from the ADAURA phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2 and 3a) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent.
Positive high-level results from a planned interim analysis of the AEGEAN phase III, placebo-controlled trial showed that treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage (2a-3b) non-small cell lung cancer.
New insights into the effects of a hormonal treatment for transgender men, discovered by Cedars-Sinai investigators, could have implications for the treatment of breast cancer.
Researchers at NCI Center for Cancer Research have identified extrachromosomal DNA as a major driver of small cell lung cancer, highlighting a novel biomarker and therapeutic target that could be used to eliminate the most aggressive and shapeshifting SCLC cells. The study was published in Cancer Discovery.
Given the lack of research into oncology-related telehealth, researchers at Trilliant Health sought to better understand the scope of oncology-related telehealth and the demographics of those patients, relative to telehealth patients writ large.
Cell membrane protrusions called blebs that typically signify the end of life for healthy cells do the opposite for melanoma cells, activating processes in these cells that help them to survive and spread, a UT Southwestern study suggests.
